CAS: 90841-46-6; Methyl 4-Bromo-2,6-Dimethylbenzoate
该化合物是一种溴化芳烃酯,分子式为C10H11BRO2.该化合物的特点是在2和6位置的4个位置和2和6位置的甲基组组中用溴取代苯甲酸酯核心,加强了其消毒和电子特性.该化合物是有机合成的多用途中间体,特别是在制药和农用化学应用中,其溴混合物能够通过交叉反应进一步发挥功能.该酯组为水解或转化提供了额外的再活动性.该组在标准条件下,其明确的结构和稳定性使它成为建造复杂分子的可靠建筑块.该化合物的供应通常具有高纯度,确保合成工作流程的一贯性能.
物理性质
MSDS等安全信息
欧盟法规
C&L通报上下游产品
methanol 4-bromo-2,6-dimethylphenyl trifluoromethanesulfonate carbon monoxide 4-bromo-2,6-dimethylbenzoic acid4-bromo-2,6-dimethylbenzoic acid methyl 4-bromo-2-(bromomethyl)-6-methylbenzoate (4-ethyl-2,6-dimethylphenyl)methanol 2-(bromomethyl)-5-ethyl-1,3-dimethylbenzene合成工艺路线路线简述
- 74346-19-3 = 90841-46-6
反应条件:1.1 Reagents: Potassium Carbonate Solvents: Dimethylformamide; Rt; Overnight,Rt
标题:Mechanistic Investigations Into Amination Of Unactivated Arenes Via Cation Radical Accelerated Nucleophilic Aromatic Substitution
作者:Pistritto,Vincent A.; Liu,Shubin; Nicewicz,David A.
参考文献:Journal Of The American Chemical Society 日期:2022 卷标:144(33) 页码:15118-15131
📜5-溴-2-碘间二甲苯置于potassium Carbonate体系中,用 四氢呋喃,N,N-二甲基甲酰胺 作为反应溶剂,化学反应 2.0H,反应生成 4-溴-2,6-二氟苯甲酸甲酯
参考文献: Bioreversable Promoieties For Nitrogen-Containing And Hydroxyl-Containing Drugs[fr] Pro-Fragments Bioréversibles Pour Médicaments Contenant De L'Azote Et De L'Hydroxyle
标题: Bioreversable Promoieties For Nitrogen-Containing And Hydroxyl-Containing Drugs[fr] Pro-Fragments Bioréversibles Pour Médicaments Contenant De L'Azote Et De L'Hydroxyle
摘要:披露了以下公式的促销性质,它们可用于形成含有氮或羟基的药物或药物活性剂的的前药:(I)以及包含这些前药的药物组合物.
海关参考信息
- 2906210000-苄醇
2912110000-甲醛
2912210000-苯甲醛
2915110000-甲酸 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:US-10112955-B2
优先权日:2015-10-29
标题 :Isoindoline, azaisoindoline, dihydroindenone and dihydroazaindenone inhibitors of Mnk1 and Mnk2
发明人：SPRENGELER PAUL A; REICH SIEGFRIED H; ERNST JUSTIN T; WEBBER STEPHEN E; SHAGHAFI MIKE; MURPHY DOUGLAS; TRAN CHINH
权利人:EFFECTOR THERAPEUTICS INC
摘要:The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. n nFor Formula I compounds A 1 , A 2 , A 3 , A 4 , A 5 , W 1 , Y, R 1 , R 2 , R 3 , R 4 , R 5 , R 6a , R 6b , R 7 , R 8 , R 8a , R 8b , R 9 , R 9a , R 9b , and R 10 and subscript “nâ€? are as defined in the specification. The inventive Formula I compounds are inhibitors of Mnk and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.
